Anavex Life Sciences Corp (AVXL)

[falconer66a]

As predicted, Anavex 3-71 next for Alzheimer’s

Based on these results, and ANAVEX®3-71 pre-clinical profile, the Company intends to advance ANAVEX®3-71 into a biomarker-driven clinical development dementia program for the treatment of FTD, schizophrenias and Alzheimer’s disease,....

https://www.anavex.com/post/anavex-life-sciences-reports-positive-results-from-phase-1-clinical-trial-of-anavex-3-71

Well, it appears that Anavex Life Sciences Corp, just as I did, sees Anavex 3-71 as a new, to-be-developed treatment for Alzheimer’s disease.

The results of the Phase I Anavex 3-71 trial, were announced:

ANAVEX®3-71 was well tolerated in all cohorts receiving ANAVEX®3-71 in single doses ranging from 5 mg to 200 mg daily with no serious adverse events (SAEs) and no significant lab abnormalities in any subject. In the study, ANAVEX®3-71 exhibited linear pharmacokinetics. Its pharmacokinetics was also dose proportional for doses up to 160 mg. Gender had no effect on the PK of the drug and food had no effect on the bioavailability of ANAVEX®3-71. The study also met the secondary objective of characterizing the effect of ANAVEX®3-71 on electrocardiogram (ECG) parameters. There were no clinically significant ECG parameters throughout the study. Participant QTcF measures were normal across all dose groups with no difference between ANAVEX®3-71 and Placebo.

All of this confirms and builds upon the previous murine, lab rodent data, from transgenic mice with genetically-induced human-type Alzheimer’s. As expected, this further confirms that sigma-1 receptor biology in murines is closely analogous to that in humans. What was seen in the rodents treated with Anavex 3-71 accurately predicted what was seen in humans. In this case, mice are (like) men.

Again, after blarcamesine for Alzheimer’s, it will be Anavex 3-71. Full clinical trials, of course, will have to be conducted, but there is not a microfragment of evidence, now in either rodents or humans that the drug will fail.

Of course, what needs yet to be determined are further, broader pleiotrophic outcomes, where sigma-1 receptor activation by the drug resolves not only Alzheimer’s, but a variety of other pathologies.